HeXun Biosciences Co (ROCO:6986) LT-Debt-to-Total-Asset : 0.05 (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is HeXun Biosciences Co LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. HeXun Biosciences Co's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.05.

HeXun Biosciences Co's long-term debt to total assets ratio declined from Dec. 2023 (0.12) to Dec. 2024 (0.05). It may suggest that HeXun Biosciences Co is progressively becoming less dependent on debt to grow their business.

HeXun Biosciences Co LT-Debt-to-Total-Asset Historical Data

The historical data trend for HeXun Biosciences Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HeXun Biosciences Co LT-Debt-to-Total-Asset Chart

HeXun Biosciences Co Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

0.28

0.24

0.17

0.12

0.05

HeXun Biosciences Co Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial			0.17	0.13	0.12	0.05	0.05

HeXun Biosciences Co LT-Debt-to-Total-Asset Calculation

HeXun Biosciences Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	31.984	/	706.919
	=	0.05

HeXun Biosciences Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	31.984	/	706.919
	=	0.05

HeXun Biosciences Co (ROCO:6986) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

HeXun Biosciences Co LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of HeXun Biosciences Co's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

HeXun Biosciences Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HeXun Biosciences Co Ltd (ROCO:6986) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

Chunri Road, 6 F., No. 1490, Taoyuan District, Taoyuan, TWN

Website

https://www.hexunbio.com

HeXun Biosciences Co Ltd is engaged in the research and development of cell drugs and cell derivatives. It conducts research and development jointly with medical research institutions to use stem cells to treat cardiovascular, immune-inflammatory, and neurodegenerative diseases to develop innovative cell drugs and treatment methods. The company's main business items are new drug research and development, biotechnology services, and research and development services, such as: commissioned research and development and production services for cell medicine, agency testing and development services, and biomedical consulting services, etc.

HeXun Biosciences Co Headlines

No Headlines